使用长期平均危险评估免疫疗法的延迟治疗益处:一种新的测试/估计方法
Miki Horiguchi1, Lu Tian2, Kenneth L Kehl3
1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Lifetime data analysis
|October 14, 2025
概括
一种新的长期平均危险 (LT-AH) 方法改善了癌症免疫疗法试验分析,当治疗效果延迟时. 这种方法提供了比传统方法更好的功率和更清晰的解释时间到事件的结果.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 癌症研究 癌症研究
背景情况:
- 延迟治疗效应在癌症免疫疗法试验中很常见.
- 传统的方法,如日志等级测试和危险比率,对于延迟的效果,缺乏功率和清晰的解释,可能是不理想的.
- 现有的替代方案包括长期受限平均生存时间 (LT-RMST) 和平均危险与生存重量 (AH-SW).
研究的目的:
- 引入一种新的长期平均危险 (LT-AH) 方法,用于测试假设和估计时间到事件分析的生存重量.
- 在癌症临床试验中处理延迟治疗效果时解决传统方法的局限性.
- 提供一个可靠和可解释的框架,以绝对和相对计算治疗效应的量化.
主要方法:
- 整合LT-RMST和AH-SW概念,以开发LT-AH方法.
- 对于个别组的LT-AH的非参数估计.
- 开发基于LT-AH差异和比率的连贯的集团间比较框架.
- 数值研究评估LT-AH的性能与现有方法相比.
主要成果:
- 与现有的替代方法相比,拟议的LT-AH方法在特定场景中显示出更高的统计能力.
- LT-AH估计是非参数的,确保测试和估计的一致性.
- 在不依赖于模型假设的情况下,LT-AH方法提供了一个可靠的框架来估计集团之间的差异.
- LT-AH允许对治疗效应进行绝对 (差异) 和相对 (比率) 量化.
结论:
- LT-AH方法为传统基于危险的方法提供了有价值的替代方案,特别是当预计会延迟治疗效果时.
- 它的解释性和在某些环境中提高的功率与临床指南建议和实际需求保持一致.
- 这种新的方法增强了癌症免疫疗法试验中延迟治疗开始的时间到事件结果的分析.
相关概念视频
01:24Kaplan-Meier Approach
526
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
526
01:20Comparing the Survival Analysis of Two or More Groups
525
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
525
01:21Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624
01:20Actuarial Approach
274
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
274
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K